Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children

Key facts

Sponsor

Sun Yat-sen University

Intervention

Pucotenlimab ,Lenvatinib(drug)

Enrollment

24 target

Eligibility

2-18 years · All sexes

Timeline

2025 – 2027

Study locations (1)

• Yizhuo Zhang, Guangdong, Guangzhou, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hepatoblastoma

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT05556642
  Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative
  Children's Hospital Medical Center, Cincinnati
• RECRUITINGPHASE1, PHASE2NCT04634357
  ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
  Eureka Therapeutics Inc.
• RECRUITINGPHASE2NCT07300449
  A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
  Sun Yat-sen University
• RECRUITINGPHASE1, PHASE2NCT04901702
  Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
  St. Jude Children's Research Hospital
• RECRUITINGPHASE3NCT04478292
  A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
  Shanghai Children's Medical Center
• ACTIVE NOT RECRUITINGPHASE3NCT03017326
  Paediatric Hepatic International Tumour Trial
  University of Birmingham
• ACTIVE NOT RECRUITINGPHASE3NCT00980460
  Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
  National Cancer Institute (NCI)

See all trials for Hepatoblastoma →